Literature DB >> 27983562

Plasma Cytokine Levels in Relation to Neuropsychiatric Symptoms and Cognitive Dysfunction in Huntington's disease.

Jos A Bouwens1,2, Erik van Duijn1,3, Christa M Cobbaert4, Raymund A C Roos5, Roos C van der Mast1,6, Erik J Giltay1.   

Abstract

BACKGROUND: In Huntington's disease (HD) the innate immune system is activated, as reflected by increased plasma levels of different cytokines.
OBJECTIVE: To explore whether increased cytokine levels are associated with neuropsychiatric symptoms and cognitive dysfunction in HD mutation carriers.
METHOD: Plasma cytokine levels of TNF-alpha, interleukin (IL)-1ra, IL-1β, IL-5, IL-6, IL-8 and Il-10 were assessed in 124 HD mutation carriers at two time points 2 years apart (totalling 214 observations). Using multilevel regression analysis, cytokines were analysed in relation to neuropsychiatric symptoms and cognitive dysfunction. Depressed mood was assessed with the depression subscale of the Problem Behaviours Assessment (PBA), apathy with the Apathy Scale, and irritability with the Irritability Scale. Cognitive functioning was assessed using the Mini-Mental State Examination (MMSE) and a battery of executive cognitive functioning tests, aggregated into an executive cognitive functioning (ExCog) score.
RESULTS: Inverse associations were found in adjusted models between IL-6 and ExCog score (β= -0.114; p = 0.01) and between IL-1ra and ExCog score (β= -0.110; p = 0.02). No associations between cytokine levels and any of the other neuropsychiatric symptom scores remained statistically significant in adjusted models.
CONCLUSION: Higher plasma levels of IL-6 and IL-1ra are weakly associated with cognitive dysfunction in HD, but not with other neuropsychiatric symptoms.

Entities:  

Keywords:  Biomarkers; Cognition; Cytokines; Neuropsychiatric symptoms; Psychopathology

Mesh:

Substances:

Year:  2016        PMID: 27983562     DOI: 10.3233/JHD-160213

Source DB:  PubMed          Journal:  J Huntingtons Dis        ISSN: 1879-6397


  6 in total

1.  Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington's Disease Patients.

Authors:  Natalia Szejko; Carmen Picón; Juan García-Caldentey; Justo Garcia de Yebenes; Jose Carlos Alvarez-Cermeño; Luisa Maria Villar; José Luis López-Sendón Moreno
Journal:  PLoS Curr       Date:  2018-08-31

2.  A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice.

Authors:  Christopher J Heath; Claire O'Callaghan; Sarah L Mason; Benjamin U Phillips; Lisa M Saksida; Trevor W Robbins; Roger A Barker; Timothy J Bussey; Barbara J Sahakian
Journal:  Front Neurol       Date:  2019-08-09       Impact factor: 4.003

3.  Levels of Interleukin-6 in Saliva, but Not Plasma, Correlate with Clinical Metrics in Huntington's Disease Patients and Healthy Control Subjects.

Authors:  Jody Corey-Bloom; Ryan S Fischer; Aeri Kim; Chase Snell; Georgia M Parkin; Douglas A Granger; Steven W Granger; Elizabeth A Thomas
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

4.  Preventive drugs for Huntington's disease: A choice-based conjoint survey of patient preferences.

Authors:  Marcus C Parrish; Andrea Hanson-Kahn; V Srinivasan; Kevin V Grimes
Journal:  J Clin Transl Sci       Date:  2022-03-01

5.  TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.

Authors:  Danielle A Simmons; Michelle L James; Nadia P Belichenko; Sarah Semaan; Christina Condon; Jason Kuan; Adam J Shuhendler; Zheng Miao; Frederick T Chin; Frank M Longo
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

Review 6.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.